FORTE BIOSCIENCES INC (FBRX) Stock Price, Quote, News and Overview
NASDAQ:FBRX - Nasdaq - US34962G2084 - Common Stock - Currency: USD
FBRX Quote, Performance and Key Statistics
NASDAQ:FBRX (6/4/2025, 1:47:48 PM)
9.96
+0.41 (+4.29%)
The current stock price of FBRX is 9.96 USD. In the past month the price increased by 43.39%. In the past year, price decreased by -34.49%.
FBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.35 | 332.90B | ||
| AMGN | AMGEN INC | 13.91 | 155.22B | ||
| GILD | GILEAD SCIENCES INC | 14.12 | 135.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 10.99 | 52.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.88B | ||
| ARGX | ARGENX SE - ADR | 100.18 | 35.17B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.61 | 27.91B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.93B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.35 | 19.35B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.02B |
Related stock screener links
About FBRX
Company Profile
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Company Info
FORTE BIOSCIENCES INC
3060 Pegasus Park Drive, Building 6
Dallas TEXAS 90502 US
CEO: Paul Wagner
Employees: 14
Phone: 13106186994
FORTE BIOSCIENCES INC / FBRX FAQ
What is the stock price of FORTE BIOSCIENCES INC today?
The current stock price of FBRX is 9.96 USD. The price increased by 4.29% in the last trading session.
What is the ticker symbol for FORTE BIOSCIENCES INC stock?
The exchange symbol of FORTE BIOSCIENCES INC is FBRX and it is listed on the Nasdaq exchange.
On which exchange is FBRX stock listed?
FBRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FORTE BIOSCIENCES INC stock?
9 analysts have analysed FBRX and the average price target is 60.18 USD. This implies a price increase of 504.22% is expected in the next year compared to the current price of 9.96. Check the FORTE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FORTE BIOSCIENCES INC worth?
FORTE BIOSCIENCES INC (FBRX) has a market capitalization of 65.54M USD. This makes FBRX a Micro Cap stock.
How many employees does FORTE BIOSCIENCES INC have?
FORTE BIOSCIENCES INC (FBRX) currently has 14 employees.
What are the support and resistance levels for FORTE BIOSCIENCES INC (FBRX) stock?
FORTE BIOSCIENCES INC (FBRX) has a support level at 8.45 and a resistance level at 10.81. Check the full technical report for a detailed analysis of FBRX support and resistance levels.
Should I buy FORTE BIOSCIENCES INC (FBRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FBRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FBRX, evaluating the profitability, health, valuation and growth aspects
- FORTE BIOSCIENCES INC (FBRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FORTE BIOSCIENCES INC (FBRX) Sales and EPS estimates to see what analysts future expectations are.
- FORTE BIOSCIENCES INC (FBRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FORTE BIOSCIENCES INC (FBRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- FORTE BIOSCIENCES INC (FBRX) Stock Chart to make your own analysis
- FORTE BIOSCIENCES INC (FBRX) Latest news and press-releases to stay up to date.
Does FORTE BIOSCIENCES INC (FBRX) stock pay dividends?
FBRX does not pay a dividend.
When does FORTE BIOSCIENCES INC (FBRX) report earnings?
FORTE BIOSCIENCES INC (FBRX) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of FORTE BIOSCIENCES INC (FBRX)?
FORTE BIOSCIENCES INC (FBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.11).
What is the Short Interest ratio of FORTE BIOSCIENCES INC (FBRX) stock?
The outstanding short interest for FORTE BIOSCIENCES INC (FBRX) is 2.42% of its float. Check the ownership tab for more information on the FBRX short interest.
FBRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to FBRX. When comparing the yearly performance of all stocks, FBRX turns out to be only a medium performer in the overall market: it outperformed 66.95% of all stocks.
FBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBRX. FBRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FBRX Financial Highlights
Over the last trailing twelve months FBRX reported a non-GAAP Earnings per Share(EPS) of -15.11. The EPS decreased by -61.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.11% | ||
| ROE | -113.76% | ||
| Debt/Equity | 0 |
FBRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to FBRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.